<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767545</url>
  </required_header>
  <id_info>
    <org_study_id>Mayer-DEX-001</org_study_id>
    <nct_id>NCT01767545</nct_id>
  </id_info>
  <brief_title>Dexamethasone-implant for the Treatment of RVO</brief_title>
  <official_title>Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of a dexamethasone-implant alone or in combination with
      bevacizumab. 64 eyes are prospectively investigated. Group 1 (22 CRVO and 16 BRVO) is treated
      with dexamethasone-implant alone, Group 2 (14 CRVO 12 BRVO) with three consecutive
      bevacizumab injections followed by a dexamethasone-implant. Recurrences are treated with
      dexamethasone-implant only. Patients are seen preoperatively and thereafter in monthly
      intervals. The primary endpoint was BCVA at twelve months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary clinical endpoint was BCVA twelve months after the first intravitreal treatment.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens opacity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saftey of procedure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Macular Edema Caused by Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Dexamethasone-implant (Group 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab/Dexamethasone-implant (Group 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone implant</intervention_name>
    <arm_group_label>Dexamethasone-implant (Group 1)</arm_group_label>
    <arm_group_label>Bevacizumab/Dexamethasone-implant (Group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Bevacizumab/Dexamethasone-implant (Group 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: maximum duration of symptoms of four months and no known history of
        glaucoma or corticosteroid response in the past -

        Exclusion Criteria: Glaucoma, Diabetic Retinopathy, prior IVOM, Uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Ophthalmology, LMU Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <last_update_submitted>January 10, 2013</last_update_submitted>
  <last_update_submitted_qc>January 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Wolfgang Mayer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

